Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of MK-1045 alone or with other anticancer therapies in non-Hodgkin lymphoma
MOH_2026-03-21_015724Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CN201 in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Merck & Co. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CN201
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2026-03-21_015724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-21_015724.